Search

Displaying results 1951 - 1960 of 10000 in total
  1. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    therapy developed by Mayne Pharma in 1992. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.

    Mixtures: DUODOPA 20 MG/ML + 5 MG/ML INTESTINAL JEL, 7 ADET, Duodopa, 20 mg/ml + 5 mg/ml, Gel zur intestinalen Anwendung
  2. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis. … It can be administered topically or orally and is only indicated in patients aged 12 years or older.

  3. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

  4. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

    Mixtures: BIS II Tooth, BIS II Tooth
  5. Drug

    Hydrocodone

    go.drugbank.com/drugs/DB00956
    ApprovedIllicitInvestigational

    The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.[L9025] … Hydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain.

    Mixtures: Novahistex Dh, Vasofrinic Dh
  6. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.

  7. Drug

    Bleselumab

    go.drugbank.com/drugs/DB15253
    Investigational

    Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney

  8. Drug

    SJG-136

    go.drugbank.com/drugs/DB11965
    Investigational

    SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and

  9. Drug

    Methenamine

    go.drugbank.com/drugs/DB06799
    ApprovedInvestigationalVet approved

    In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate which is the hippuric acid salt of methenamine). … Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.

    Mixtures: All-In-One UTI Emergency Kit, All-In-One UTI Emergency Kit
  10. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    Dordaviprone is a first-in-class small molecule imipridone. On August 6, 2025, dordaviprone was granted accelerated approval by the FDA. … [L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.